Navigation Links
Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Date:4/17/2017

SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled for Thursday, April 27, 2017, at 9:55 am ET.

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com

Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-arm-5th-annual-cell--gene-therapy-investor-day-300440070.html


'/>"/>
SOURCE Audentes Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
2. Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
3. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
4. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
8. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
9. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
10. FACIT Announces Investment in Propellon Therapeutics
11. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... and OXFORD, England , Aug. 16, ... consortium for biotech executive search and leadership development, and Virdis ... sectors, have created an exclusive alliance that enables clients to ... "For our clients here in the ... unparalleled access to a diverse population of leadership talent throughout ...
(Date:8/15/2017)... Boston, MA (PRWEB) , ... August 15, 2017 , ... ... unmet need that has compromised these disciplines for more than half a century. ... cannot be counted. It is widely known that molecular tags developed for this ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... characterized and performing antibodies. Key researchers in the antibody community have recently come ... and consistency for antibodies in the laboratory. , The team at ...
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS ... is the key structural element skin needs to maintain its youthful appearance and Algenist ... First to market with proprietary collagen water active , ...
Breaking Biology Technology:
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ... board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to ... Delta,s biometric ... Sky Club is now integrated into the boarding process to allow ...
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
Breaking Biology News(10 mins):